Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice

Molecular Nutrition and Food Research

Volumn 58, Issue 4, 2014, Pages 903-907

  Weidner, Christopher ^a,b   Wowro, Sylvia J ^a   Freiwald, Anja ^a   Kodelja, Vitam ^a   Abdel Aziz, Heba ^c   Kelber, Olaf ^c   Sauer, Sascha ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Steigerwald Arzneimittelwerk GmbH   (Germany)

Author keywords

Diabetes; Dyslipidemia; Functional Food; Melissa officinalis; Peroxisome proliferator activated receptor

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT;

ADIPOCYTE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; HUMAN; INSULIN RESISTANCE; MELISSA OFFICINALIS; METABOLISM; MOUSE MUTANT;

ADIPOCYTES; ANIMALS; CELLS, CULTURED; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; MELISSA; MICE, INBRED C57BL; MICE, OBESE; PLANT EXTRACTS; PPAR ALPHA; PPAR GAMMA;

EID: 84897042175     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300477     Document Type: Article

References (23)

1. Smyth, S., Heron, A., Diabetes and obesity: the twin epidemics. Nat. Med. 2006, 12, 75-80.
2. Kliewer, S. A., Xu, H. E., Lambert, M. H., Willson, T. M., Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 2001, 56, 239-263.
3. Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K. et al., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58, 726-741.
4. Berger, J., Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
5. [Anon], Regulators restrict Avandia in the US and suspend it in the EU. Nat. Rev. Drug Discov. 2010, 9, 828-828.
6. Pourcet, B., Fruchart, J. C., Staels, B., Glineur, C., Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin. Emerg. Drugs 2006, 11, 379-401.
7. Bailey, C. J., Learning from tesaglitazar. Diab. Vasc. Dis. Res. 2007, 4, 161-162.
8. Quideau, S., Deffieux, D., Douat-Casassus, C., Pouysegu, L., Plant polyphenols: chemical properties, biological activities, and synthesis. Angew. Chem. Int. Ed. Engl. 2011, 50, 586-621.
9. Weidner, C., de Groot, J. C., Prasad, A., Freiwald, A. et al., Amorfrutins are potent antidiabetic dietary natural products. Proc. Natl. Acad. Sci. USA 2012, 109, 7257-7262.
10. Muller, M., Kersten, S., Nutrigenomics: goals and strategies. Nat. Rev. Genet. 2003, 4, 315-322.
11. Kroll, U., Cordes, C., Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006, 13, 12-19.
12. Wegener, T., Wagner, H., The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine 2006, 13, 20-35.
13. Spiegelman, B. M., Frank, M., Green, H., Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J. Biol. Chem. 1983, 258, 10083-10089.
14. Feldmann, R., Fischer, C., Kodelja, V., Behrens, S. et al., Genome-wide analysis of LXRalpha activation reveals new transcriptional networks in human atherosclerotic foam cells. Nucl. Acids Res. 2013, 41, 3518-3531.
15. Feldmann, R., Geikowski, A., Weidner, C., Witzke, A. et al., Foam cell specific LXRalpha ligand. PLoS One 2013, 8, e57311.
16. Weidner, C., Wowro, S. J., Freiwald, A., Kawamoto, K. et al., Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with potent glucose-lowering properties. Diabetologia 2013, 56, 1802-1812.
17. Ulbricht, C., Brendler, T., Gruenwald, J., Kligler, B. et al., Lemon balm (Melissa officinalis L.): an evidence-based systematic review by the Natural Standard Research Collaboration. J. Herb. Pharmacother. 2005, 5, 71-114.
18. Chung, M. J., Cho, S. Y., Bhuiyan, M. J., Kim, K. H., Lee, S. J., Anti-diabetic effects of lemon balm (Melissa officinalis) essential oil on glucose- and lipid-regulating enzymes in type 2 diabetic mice. Br. J. Nutr. 2010, 104, 180-188.
19. Jun, H. J., Lee, J. H., Jia, Y., Hoang, M. H. et al., Melissa officinalis essential oil reduces plasma triglycerides in human apolipoprotein E2 transgenic mice by inhibiting sterol regulatory element-binding protein-1c-dependent fatty acid synthesis. J. Nutr. 2012, 142, 432-440.
20. Bolkent, S., Yanardag, R., Karabulut-Bulan, O., Yesilyaprak, B., Protective role of Melissa officinalis L. extract on liver of hyperlipidemic rats: a morphological and biochemical study. J. Ethnopharmacol. 2005, 99, 391-398.
21. Fecka, I., Turek, S., Determination of water-soluble polyphenolic compounds in commercial herbal teas from Lamiaceae: peppermint, melissa, and sage. J. Agric. Food Chem. 2007, 55, 10908-10917.
22. Mueller, M., Lukas, B., Novak, J., Simoncini, T. et al., Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J. Agric. Food Chem. 2008, 56, 11621-11630.
23. Wagner, H., Ulrich-Merzenich, G., Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009, 16, 97-110.